CN109414492A - 针对cd81的人源化和嵌合单克隆抗体 - Google Patents

针对cd81的人源化和嵌合单克隆抗体 Download PDF

Info

Publication number
CN109414492A
CN109414492A CN201780040994.1A CN201780040994A CN109414492A CN 109414492 A CN109414492 A CN 109414492A CN 201780040994 A CN201780040994 A CN 201780040994A CN 109414492 A CN109414492 A CN 109414492A
Authority
CN
China
Prior art keywords
antibody
seq
human
cell
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780040994.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·利维
A·马拉贝利
R·拉贾帕克萨
F·文塞斯-卡塔兰
郭琼玑
刘劼
R·利维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN109414492A publication Critical patent/CN109414492A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780040994.1A 2016-06-16 2017-06-14 针对cd81的人源化和嵌合单克隆抗体 Pending CN109414492A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351054P 2016-06-16 2016-06-16
US62/351,054 2016-06-16
PCT/US2017/037533 WO2017218691A1 (en) 2016-06-16 2017-06-14 Humanized and chimeric monoclonal antibodies to cd81

Publications (1)

Publication Number Publication Date
CN109414492A true CN109414492A (zh) 2019-03-01

Family

ID=60664252

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780040994.1A Pending CN109414492A (zh) 2016-06-16 2017-06-14 针对cd81的人源化和嵌合单克隆抗体

Country Status (9)

Country Link
US (1) US10815306B2 (https=)
EP (1) EP3471762A4 (https=)
JP (1) JP2019517813A (https=)
CN (1) CN109414492A (https=)
BR (1) BR112018076247A2 (https=)
CA (1) CA3027942A1 (https=)
MA (1) MA45404A (https=)
RU (1) RU2019100102A (https=)
WO (1) WO2017218691A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115551538A (zh) 2020-01-21 2022-12-30 拓维创新生物科技(香港)有限公司 干扰IL-1β受体信号转导的药剂
EP4602372A1 (en) 2022-10-12 2025-08-20 Institut National de la Santé et de la Recherche Médicale Cd81 as a biomarker and biotarget in t-cell malignancies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101213297A (zh) * 2005-05-09 2008-07-02 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
CN103249833A (zh) * 2010-12-06 2013-08-14 大日本住友制药株式会社 人单克隆抗体
WO2014063368A1 (zh) * 2012-10-26 2014-05-01 中国医学科学院基础医学研究所 抗人死亡受体5胞外区的人源化单克隆抗体
US20150139990A1 (en) * 2010-12-06 2015-05-21 Sumitomo Dainippon Pharma Co., Ltd. Human monoclonal antibody

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
AU2005291486A1 (en) 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian EAG1 ion channel protein
EP1885396A2 (en) 2005-05-04 2008-02-13 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
US20140030771A1 (en) 2010-06-09 2014-01-30 Richard C. Yu Compositions and methods for increasing oil production and secretion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101213297A (zh) * 2005-05-09 2008-07-02 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
CN103249833A (zh) * 2010-12-06 2013-08-14 大日本住友制药株式会社 人单克隆抗体
US20150139990A1 (en) * 2010-12-06 2015-05-21 Sumitomo Dainippon Pharma Co., Ltd. Human monoclonal antibody
WO2014063368A1 (zh) * 2012-10-26 2014-05-01 中国医学科学院基础医学研究所 抗人死亡受体5胞外区的人源化单克隆抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GILBERT,D.ET AL.: ""Ig kappa chain V-J region(4B1 VL)-mouse（fragment) PIR:S43103"", 《GENBANK》 *
JOHN L. XU ET AL.: ""Diversity in the CDR3 Region of VH Is Sufficient for Most Antibody Specificities"", 《IMMUNITY》 *

Also Published As

Publication number Publication date
RU2019100102A (ru) 2020-07-16
EP3471762A4 (en) 2020-03-11
US10815306B2 (en) 2020-10-27
WO2017218691A1 (en) 2017-12-21
EP3471762A1 (en) 2019-04-24
JP2019517813A (ja) 2019-06-27
CA3027942A1 (en) 2017-12-21
BR112018076247A2 (pt) 2019-03-26
MA45404A (fr) 2019-04-24
US20190177425A1 (en) 2019-06-13
RU2019100102A3 (https=) 2020-10-14

Similar Documents

Publication Publication Date Title
Carter et al. Next generation antibody drugs: pursuit of the'high-hanging fruit'
US10781256B2 (en) Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies
TWI871272B (zh) 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
KR102878970B1 (ko) 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
JP6850255B2 (ja) 抗−ｃｄ４７抗体及びその使用
CN109641049A (zh) Cd3结合抗体
CN108738324A (zh) 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
RS66543B1 (sr) Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela
CN109476740A (zh) 利用抗cd73抗体的联合治疗
CN109843325A (zh) Cd3结合抗体
TW201726713A (zh) 最優化抗ｃｄ３雙特異性抗體及其用途
US20220372161A1 (en) Antibodies against the poliovirus receptor (pvr) and uses thereof
WO2022262868A1 (zh) 一种双抗组合及其应用
TW202309088A (zh) 新的穩定抗ｖｉｓｔａ抗體
WO2019226658A1 (en) Multispecific antigen-binding compositions and methods of use
US9447160B2 (en) Compositions, methods and kits for treatment of cancer and autoimmune diseases
CN109414492A (zh) 针对cd81的人源化和嵌合单克隆抗体
WO2024235317A1 (zh) 结合lilrb4和cd3的抗体及其用途
JP2025537255A (ja) 抗アルファ５インテグリン抗体及びその使用
US12606617B2 (en) Composition comprising an IgE antibody
WO2022267926A1 (zh) 一种抗tnfr2抗体及其制备方法和应用
KR102956480B1 (ko) 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
TW202602924A (zh) 抗ccr8抗體之醫藥配製物
TW202608923A (zh) Ｌｔｂｒ結合分子及其用途
CN121693520A (zh) 靶向肿瘤相关抗原与cd28的双特异性抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003752

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190301

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40003752

Country of ref document: HK